Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Analysis of Extemporaneous Alprostadil Formulations

Author(s):  Sarver Jeffrey G, Peng Ning, Lerdkanchanaporn Supaporn, Oravecz-Wilson Katherine, Alexander Kenneth S, Erhardt Paul W

Issue:  Mar/Apr 1999 - Compounding for Men's Health
View All Articles in Issue

Page(s):  148-155

Analysis of Extemporaneous Alprostadil Formulations Page 1
Analysis of Extemporaneous Alprostadil Formulations Page 2
Analysis of Extemporaneous Alprostadil Formulations Page 3
Analysis of Extemporaneous Alprostadil Formulations Page 4
Analysis of Extemporaneous Alprostadil Formulations Page 5
Analysis of Extemporaneous Alprostadil Formulations Page 6
Analysis of Extemporaneous Alprostadil Formulations Page 7
Analysis of Extemporaneous Alprostadil Formulations Page 8

Download in electronic PDF format for $75

Abstract:  Twenty-two extemporaneous alprostadil (PGE1) injection solution samples from five different suppliers and three Caverject ® (Pharmacia & Upjohn, Inc., Bridgewater, NJ) samples from three different lots, all intended for the clinical treatment of erectile dysfunction, were analyzed to determine PGE1 concentration, assess formation of the PGE1 aqueous breakdown product (PGA1), define pH and assess active microbial contamination. High-pressure liquid chromatography (HPLC), pH meter and cell culture techniques were used to conduct the analyses. Of the 22 extemporaneously formulated samples, six showed PGE1 concentrations 10% greater than their listed amounts and seven showed PGA1 weight fractions corresponding to at least 1.5% of the total prostaglandin content. It should be noted that no standard has been published in the United States Pharmacopeia/National Formulary for this preparation as of this date. All samples were within the pH range 4.5 to 6.0. Four samples tested positive for active microbial contamination. In addition, nearly all the extemporaneously formulated samples contained what appeared to be benzyl alcohol, and about one half had at least two other undefined peaks within their HPLC chromatograms. In contrast, all three Caverject samples were within ± 7.5% of their listed PGE1 concentrations while showing PGA1 prostaglandin weight fractions of less than 0.6%, all were within the pH range 4.0 to 4.5 and all tested negative for active microbial contamination. Chromatograms of the Caverject samples also displayed peaks consistent with the presence of benzyl alcohol but did not exhibit additional undefined peaks. The results suggest that significant variations in PGE1 concentration and in PGA1 formation, accompanied by the possibility of microbial contamination, can occur as a result of the extemporaneous formulation and subsequent transfer of this type of product as a premixed solution intended for treating erectile dysfunction.

Related Keywords: alprostadil, PGE1, erectile dysfunction, Caverject, microbial contamination, aqueous breakdown

Related Categories: PEDIATRICS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, QUALITY CONTROL

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Analysis of Extemporaneous Alprostadil Formulations
Sarver Jeffrey G
, Peng Ning, Lerdkanchanaporn Supaporn, Oravecz-Wilson Katherine, Alexander Kenneth S, Erhardt Paul W
Mar/Apr 1999
Pg. 148-155

Long-Term Stability of Trimix: A Three-Drug Injection Used to Treat Erectile Dysfunction.
Trissel Lawrence A
, Zhang Yanping
May/Jun 2004
Pg. 231-235

Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
May/Jun 2003
Pg. 170-174

Reversing Erectile Dysfunction and Urinary Incontinence After Prostatectomy or Radiotherapy: The Stanley Prostate-Cancer Treatment Protocol
McKettrick Greg
, Yoch Doug
Jan/Feb 2021
Pg. 18-23

Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers
McCluskey Susan V
, Kirkham Kylian, Munson Jessica M
Mar/Apr 2017
Pg. 150-153

Compounded Treatments for Erectile Dysfunction: A Common Complication of Diabetes
Fields Shannon W
Mar/Apr 2007
Pg. 122-124

Determining the Causes of Erectile Dysfunction: Can Medications Be a Double-Sided Sword?
Williams LaVonn A
Mar/Apr 2010
Pg. 105-107

Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S
, Thyangarajapuram N
Sep/Oct 2003
Pg. 389-393

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin
, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
May/Jun 2003
Pg. 233-239

The Stanley Prostate-cancer Treatment Protocol for Erectile Dysfunction After Prostatectomy and/or Radiotherapy: A Case Report
McKettrick Greg
, Yoch Doug
Mar/Apr 2021
Pg. 94-98

Male Impotency and the Compounding Pharmacist
Preckshot John
Mar/Apr 1999
Pg. 80-83

Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women
Mason Dave
Jul/Aug 2002
Pg. 255-256

Compounding Opportunities in Urology
Biundo Bruce
Sep/Oct 2017
Pg. 358-362

Extemporaneous Formulation and Stability Testing of Mexiletine HCl Solution
Alexander Kenneth S
, Kaushik Sarita
Mar/Apr 2004
Pg. 147-152

Quality Control Analytical Methods: Microbial Limit Tests for Nonsterile Pharmaceuticals, Part 1
Vu Nicole
, Lou Jessica R, Kupiec Thomas
May/Jun 2014
Pg. 213-221

Quality Control: Microbial Limit Tests for Nonsterile Pharmaceuticals, Part 2
Vu Nicole
, Lou Jessica R, Kupiec Thomas C
Jul/Aug 2014
Pg. 305-310

Basics of Sterile Compounding: Contamination Control
Akers Michael J
May/Jun 2015
Pg. 232-238

Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design
Patel Gopesh
, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
Jan/Feb 2021
Pg. 73-81

Sterile Basics of Compounding: Contamination Control Strategies, Part 2
Summers Amy
Nov/Dec 2022
Pg. 497-504

Establishing Benchmark Rates of Microbial and Bacterial Endotoxin Contamination for Radiopharmaceuticals Compounded in Commerical Nuclear Pharmacy Settings
Weatherman Kara D
, Augustine Samuel, Christoff Jeffrey, Galbraith Wendy
Mar/Apr 2013
Pg. 168-174

Return to Top